Gt Biopharma, INC. (GTBP) — SEC Filings

Overview

Gt Biopharma, INC. (GTBP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 7, 2026: GT Biopharma, Inc. filed an 8-K on April 7, 2026, reporting the entry into a material definitive agreement on April 3, 2026. The filing also includes financial statements and exhibits related to this agreement.

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 3 bearish, 33 neutral, 4 mixed. The dominant filing sentiment for Gt Biopharma, INC. is neutral.

Filing Type Overview

Gt Biopharma, INC. (GTBP) has filed 22 8-K, 6 10-Q, 3 S-1, 2 S-1/A, 1 10-K/A, 2 10-K, 1 DEFA14A, 2 SC 13G/A, 1 DEF 14A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (40)

• GT Biopharma Files 8-K for Material Agreement — 8-K · Apr 7, 2026 Risk: medium
  GT Biopharma, Inc. filed an 8-K on April 7, 2026, reporting the entry into a material definitive agreement on April 3, 2026. The filing also includes financial
• GT Biopharma Faces Delisting Concerns — 8-K · Nov 26, 2025 Risk: high
  GT Biopharma, Inc. filed an 8-K on November 26, 2025, reporting a notice of delisting or failure to meet continued listing requirements. The filing also include
• GT Biopharma Narrows Losses, Equity Turns Positive Amid Cash Burn — 10-Q · Nov 14, 2025 Risk: high
  GT Biopharma, Inc. reported a net loss of $5.3 million for the nine months ended September 30, 2025, a significant improvement from the $9.387 million net loss
• GT Biopharma Registers 14.6M Shares for Resale, Cites Going Concern Doubt — S-1 · Oct 24, 2025 Risk: high
  GT Biopharma, Inc. (GTBP) filed an S-1 to register 14,589,546 shares of common stock for resale by selling stockholders, stemming from a May 2025 private placem
• GT Biopharma Files 8-K on Security Holder Rights — 8-K · Sep 26, 2025 Risk: medium
  GT Biopharma, Inc. filed an 8-K on September 25, 2025, reporting material modifications to the rights of security holders and financial statements. The company,
• GT Biopharma Files 8-K on Security Holder Rights — 8-K · Sep 23, 2025 Risk: medium
  GT Biopharma, Inc. filed an 8-K on September 23, 2025, reporting events as of September 17, 2025. The filing indicates material modifications to the rights of s
• GT Biopharma Reports Director Changes and Officer Compensation — 8-K · Aug 29, 2025 Risk: medium
  GT Biopharma, Inc. filed an 8-K on August 26, 2025, reporting the departure of director Dr. Jonathan M. Roth and the election of new director Dr. David L. Smith
• GT Biopharma Narrows Losses, Raises Capital Amid Going Concern Doubts — 10-Q · Aug 14, 2025 Risk: high
  GT Biopharma, Inc. reported a net loss of $2.2 million for the six months ended June 30, 2025, a significant improvement from the $5.98 million net loss in the
• GT Biopharma Files 8-K on Security Holder Vote — 8-K · Jul 24, 2025 Risk: low
  GT Biopharma, Inc. filed an 8-K on July 24, 2025, to report on the submission of matters to a vote of its security holders. The filing does not contain specific
• GT Biopharma Amends S-1, Signals Capital Raise Intent — S-1/A · Jun 27, 2025 Risk: high
  GT Biopharma, Inc. (GTBP) filed an S-1/A on June 27, 2025, for a delayed and continuous offering of securities under Rule 415, indicating a capital raise withou
• GT Biopharma Files 8-K on Agreements and Personnel Changes — 8-K · Jun 11, 2025 Risk: medium
  GT Biopharma, Inc. filed an 8-K on June 11, 2025, reporting on a material definitive agreement, the departure of directors or certain officers, election of dire
• GT Biopharma Reports Material Definitive Agreement & Equity Sales — 8-K · May 27, 2025 Risk: medium
  GT Biopharma, Inc. filed an 8-K on May 27, 2025, reporting on several events that occurred on May 21, 2025. These include entering into a material definitive ag
• GT Biopharma Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: low
  GT Biopharma, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS I
• GT Biopharma Files 8-K on Material Agreements & Equity Sales — 8-K · May 13, 2025 Risk: medium
  GT Biopharma, Inc. filed an 8-K on May 13, 2025, reporting on several material events as of May 12, 2025. These include entering into a material definitive agre
• GT Biopharma Reports Director/Officer Changes — 8-K · May 5, 2025 Risk: medium
  GT Biopharma, Inc. filed an 8-K on April 29, 2025, reporting changes in its board of directors and executive officers, as well as updates to compensatory arrang
• GT Biopharma Files 2024 Annual Report Amendment — 10-K/A · Apr 14, 2025 Risk: low
  GT Biopharma, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing was made on April 14, 2025, and it a
• GT Biopharma Reports Unregistered Equity Sales — 8-K · Apr 4, 2025 Risk: medium
  GT Biopharma, Inc. filed an 8-K on April 4, 2025, reporting unregistered sales of equity securities as of March 31, 2025. The filing also includes financial sta
• GT Biopharma Files 8-K on Agreements and Equity Sales — 8-K · Feb 26, 2025 Risk: medium
  GT Biopharma, Inc. filed an 8-K on February 25, 2025, reporting on the entry into a material definitive agreement and unregistered sales of equity securities. T
• GT Biopharma Files 2024 Annual Report — 10-K · Feb 21, 2025 Risk: medium
  GT Biopharma, Inc. filed its 10-K for the fiscal year ending December 31, 2024, on February 21, 2025. The company, formerly known as OXIS INTERNATIONAL INC, is
• GT Biopharma Files S-1/A Amendment — S-1/A · Feb 7, 2025 Risk: medium
  GT Biopharma, Inc. filed an S-1/A amendment on February 7, 2025, for its registration statement. The company, formerly known as OXIS INTERNATIONAL INC, DDI PHAR
• 8-K Filing — 8-K · Jan 27, 2025
• GT Biopharma Files S-1 Registration — S-1 · Dec 23, 2024 Risk: medium
  GT Biopharma, Inc. filed an S-1 registration statement with the SEC on December 23, 2024. The company, previously known as OXIS INTERNATIONAL INC, DDI PHARMACEU
• GT Biopharma Faces Delisting Concerns — 8-K · Nov 27, 2024 Risk: high
  GT Biopharma, Inc. filed an 8-K on November 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, p
• GT Biopharma Files 8-K for Material Agreement — 8-K · Nov 21, 2024 Risk: medium
  GT Biopharma, Inc. filed an 8-K on November 21, 2024, reporting an entry into a material definitive agreement and financial statements. The filing date for the
• GT Biopharma Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  GT Biopharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first nine mont
• GT Biopharma Reports Director and Officer Changes — 8-K · Sep 16, 2024 Risk: medium
  GT Biopharma, Inc. filed an 8-K on September 16, 2024, reporting changes in its board of directors and certain officers, as well as updates to compensatory arra
• 10-Q Filing — 10-Q · Aug 14, 2024
• GT Biopharma Files 8-K — 8-K · Jun 27, 2024 Risk: low
  GT Biopharma, Inc. filed an 8-K on June 27, 2024, reporting other events and financial statements. The company, formerly known as OXIS INTERNATIONAL INC, DDI PH
• GT Biopharma Files 8-K on Security Holder Vote Matters — 8-K · Jun 26, 2024 Risk: medium
  GT Biopharma, Inc. filed an 8-K on June 25, 2024, to report on matters submitted to a vote of its security holders. The filing indicates a change in the company
• GT Biopharma Files S-1 Registration Statement — S-1 · Jun 20, 2024 Risk: medium
  GT Biopharma, Inc. filed an S-1 registration statement on June 18, 2024, to register securities. The company, formerly known as OXIS INTERNATIONAL INC, DDI PHAR
• GT Biopharma Files Additional Proxy Materials — DEFA14A · Jun 17, 2024 Risk: low
  GT Biopharma, Inc. filed a Definitive Additional Materials proxy statement on June 17, 2024. The filing concerns matters related to the company's proxy statemen
• GT Biopharma Reports Director/Officer Changes and Compensation — 8-K · Jun 7, 2024 Risk: medium
  GT Biopharma, Inc. filed an 8-K on June 7, 2024, reporting on events that occurred on June 3, 2024. The filing primarily concerns the departure of directors or
• SC 13G/A Filing — SC 13G/A · May 23, 2024
• GT Biopharma Files 8-K: Material Agreement & Equity Sales — 8-K · May 23, 2024 Risk: medium
  GT Biopharma, Inc. announced on May 21, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity se
• GT Biopharma, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: low
  GT Biopharma, Inc. (GTBP) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. GT Biopharma, Inc. filed a 10-Q report for the period ending March 31, 2
• GT Biopharma Enters Material Definitive Agreement — 8-K · Apr 30, 2024 Risk: medium
  GT Biopharma, Inc. entered into a Material Definitive Agreement on April 25, 2024. The filing also includes financial statements and exhibits related to this ag
• GT Biopharma, Inc. Announces Annual Meeting of Stockholders on June 25, 2024 — DEF 14A · Apr 29, 2024 Risk: low
  GT Biopharma, Inc. (GTBP) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. GT Biopharma, Inc. will hold its Annual Meeting of Stockholders on J
• GT Biopharma, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 26, 2024 Risk: medium
  GT Biopharma, Inc. (GTBP) filed a Annual Report (10-K) with the SEC on March 26, 2024. GT Biopharma, Inc. filed its 2023 Form 10-K on March 26, 2024. The compan
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• GT Biopharma Files 8-K: Security Holder Rights, Bylaw Amendments — 8-K · Feb 1, 2024
  GT Biopharma, Inc. filed an 8-K on February 1, 2024, to report material modifications to the rights of its security holders and amendments to its Articles of In

Risk Profile

Risk Assessment: Of GTBP's 35 recent filings, 6 were flagged as high-risk, 22 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Gt Biopharma, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $0
• Net Income: -$5.3M
• EPS: -$0.83
• Debt-to-Equity: N/A
• Cash Position: $2.528M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Michael Breen
• Alan A. Lanis, Jr.
• Dr. Jeffrey Miller
• Dr. Jonathan M. Roth
• Dr. David L. Smith

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like GT Biopharma often operate at a loss for extended periods, relying on external financing until a product gains regulatory approval and market traction. The competitive landscape is intense, with both large pharmaceutical firms and smaller biotech companies vying for market share.

Top Tags

material-agreement (7) · filing (6) · financials (5) · corporate-action (4) · corporate-governance (4) · management-change (4) · equity-sale (4) · pharmaceuticals (4) · Biotechnology (3) · Going Concern (3)

Key Numbers

• Net Loss: $5.3M — Reduced from $9.387M in prior year, a 43% improvement.
• Cash Used in Operations: $8.893M — Decreased from $10.436M in prior year, indicating improved cash management.
• Total Stockholders' Equity: $3.000M — Shifted from a $1.670M deficit, indicating successful capital raises.
• Cash and Cash Equivalents: $2.528M — Down from $3.951M at year-end 2024, highlighting ongoing cash burn.
• Research and Development Expenses: $2.096M — Decreased from $3.868M in prior year, a 45.8% reduction.
• Selling, General and Administrative Expenses: $4.731M — Decreased from $6.733M in prior year, a 29.7% reduction.
• Proceeds from Series L Convertible Preferred Stock: $6.503M — Key financing activity contributing to positive equity.
• Revenue: 0 — No revenue generated, typical for a clinical-stage biopharma.
• Deferred Offering Costs: $0.8M — Capitalized for in-process equity financings, indicating future capital raise efforts.
• Net Loss Per Share (Q3 2025): $0.83 — Improved from $1.53 in Q3 2024, despite increased share count.
• Shares of Common Stock: 14,589,546 — Total shares registered for resale by selling stockholders
• Conversion Shares: 7,219,771 — Shares issuable upon conversion of Series L Preferred Stock
• Vesting Warrant Shares: 7,219,775 — Shares issuable upon exercise of vested warrants
• Advisory Shares: 150,000 — Shares issuable upon exercise of pre-funded warrants to PDPC Advisors Inc.
• Closing Sale Price: $0.73 — GTBP common stock price on October 23, 2025

Frequently Asked Questions